Larazotide Acetate

Quick Facts

Introduction

Larazotide acetate (also known by its research designation AT-1001) is a synthetic octapeptide studied as a tight-junction regulator — a molecule that influences the sealing structures between intestinal epithelial cells. Its central research theme is the integrity of the gut barrier, specifically the paracellular permeability that, when increased, is informally referred to as 'leaky gut.' This makes larazotide a distinctive entry among recovery-focused peptides because its proposed action is on the barrier itself rather than on tissue growth or inflammation directly.

Within the peptide database, larazotide is often discussed alongside other compounds studied for gastrointestinal recovery, such as BPC-157 and the anti-inflammatory tripeptide KPV. Where those peptides are studied for tissue repair and inflammation, larazotide is studied for restoring barrier function by counteracting the signals that open tight junctions — most notably the protein zonulin.

This profile covers what larazotide acetate is, its octapeptide structure, the tight-junction biology behind it, its proposed mechanism as a zonulin antagonist, the intestinal-barrier and celiac-disease research contexts it appears in, and how it compares with related gut-focused peptides. It is among the more clinically studied peptides in this catalogue, which shapes both its evidence base and its limitations.

What is larazotide acetate?

Larazotide acetate is a synthetic eight-amino-acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) developed specifically as a regulator of intestinal tight junctions. It was designed to act locally within the gut lumen, where it can interact with the apical surface of epithelial cells, rather than being absorbed to act systemically — a deliberate feature that shapes its pharmacology and safety profile.

The biological rationale comes from research on zonulin, an endogenous protein that, when released, triggers the reversible opening of tight junctions and increases paracellular permeability. Excess permeability has been associated in research with the passage of luminal antigens across the epithelium, a process implicated in celiac disease and studied more broadly in other conditions involving barrier dysfunction. Larazotide is studied as an agent that opposes this opening.

Molecular and structural characteristics

Larazotide is a small, linear octapeptide. Its modest size and amino-acid composition are consistent with its design as a luminally-acting agent: rather than crossing the epithelium to reach the bloodstream, it is intended to engage targets at the apical cell surface and then be cleared with the gut contents. This local-action profile is central to how its research is interpreted.

Because it works at the barrier interface, the relevant 'pharmacokinetics' for larazotide are less about systemic exposure and more about local concentration and persistence in the intestine. The acetate salt form is used to improve handling and solubility of the peptide for research preparations.

Mechanism of action

Larazotide's proposed mechanism is tight-junction stabilization. Tight junctions are protein complexes — including occludin, claudins, and zonula occludens (ZO) proteins — that seal the space between adjacent epithelial cells and govern paracellular permeability. When zonulin signaling opens these junctions, larazotide is studied as an agent that opposes the opening and promotes reassembly, helping to restore barrier integrity.

Mechanistically, research describes larazotide as interfering with the zonulin pathway and with the actin cytoskeleton rearrangement that accompanies tight-junction disassembly. By preventing the cytoskeletal contraction and tight-junction protein redistribution that widen the paracellular space, the peptide is associated with reduced permeability and reduced passage of luminal antigens across the epithelium.

This is a fundamentally different mechanism from that of inflammation-focused peptides like KPV, which act on NF-κB signaling, or tissue-repair peptides like BPC-157, which are studied for angiogenic effects. Larazotide's target is the physical barrier itself, which is why it is categorized as a tight-junction regulator rather than an anti-inflammatory or growth-promoting agent.

• Opposes zonulin-driven opening of intestinal tight junctions.
• Promotes reassembly of tight-junction protein complexes.
• Inhibits the actin-cytoskeleton rearrangement that widens junctions.
• Reduces paracellular permeability and antigen passage.
• Acts locally at the apical epithelial surface.

Intestinal-barrier and celiac-disease research

The most developed research context for larazotide is celiac disease, an immune-mediated condition in which gluten exposure drives increased intestinal permeability and mucosal damage. Larazotide has been studied in controlled clinical trials as an investigational agent intended to reduce gluten-associated permeability and symptoms in study populations already following a gluten-free diet, making it one of the more clinically advanced peptides in this catalogue.

Beyond celiac disease, the broader concept of barrier dysfunction ('leaky gut') connects larazotide to research across a range of conditions in which increased permeability is hypothesized to contribute to immune activation. In these contexts it is studied conceptually alongside gut-recovery peptides catalogued in the peptide database, though the evidence base outside celiac disease is far more preliminary.

Gut-recovery and permeability research

Because barrier integrity intersects with so many gastrointestinal processes, larazotide is also examined more broadly in gut-recovery research. The premise is that stabilizing tight junctions could limit the downstream immune consequences of a compromised barrier, complementing approaches that target inflammation or tissue repair. Within recovery-focused peptides it sits alongside compounds such as GLP-2 (Glepaglutide), which is studied for intestinal trophic effects rather than barrier sealing.

The distinction is instructive: larazotide does not stimulate intestinal growth or directly suppress inflammation; it is studied specifically for modulating permeability. This narrow, well-defined mechanism is both its scientific appeal and a reminder that it addresses one component of gut health rather than serving as a general-purpose recovery agent.

Comparison: Larazotide acetate vs BPC-157 vs GLP-2

Larazotide is usefully compared with BPC-157, a tissue-repair peptide studied in gut contexts, and GLP-2 (Glepaglutide), an intestinal trophic peptide. All three appear in gastrointestinal recovery research but address different aspects of gut biology.

Where BPC-157 is studied for repair and GLP-2 for intestinal growth, larazotide is studied specifically for barrier permeability — illustrating how complementary gut-focused peptides target distinct processes. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

Larazotide's pharmacokinetics are unusual among research peptides because it is designed to be minimally absorbed. Rather than achieving a systemic concentration, the relevant exposure is local within the intestinal lumen, where the peptide engages the apical epithelial surface before being cleared with gut contents. This means conventional systemic half-life is less informative than local persistence in the gut.

This local-action design also shapes how research is interpreted: because larazotide is intended to act at the site of barrier dysfunction, timing relative to luminal triggers (such as a meal containing the relevant antigen) is a recurring consideration in study design rather than blood-level kinetics.

Reconstitution and handling considerations

Lyophilized larazotide acetate is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. The resulting solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized larazotide acetate is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled through freeze–thaw.

Research limitations

Larazotide is a research compound whose clinical study has centered on celiac-disease endpoints. Its benefits are tied to a specific, narrow mechanism (tight-junction regulation), the broader 'leaky gut' applications remain hypothesis-generating, and even within celiac research outcomes are dependent on study design and population. It is described here strictly for research reference.

• Clinical research has focused mainly on celiac-disease endpoints.
• Its mechanism addresses permeability, not inflammation or tissue growth.
• Broader 'leaky gut' applications remain preliminary.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015.Source
2. Khaleghi S, et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016.Source
3. Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007.Source